Oncology in advanced and resistant disease
CatalYm GmbH focuses on clinical research in advanced-stage solid tumors and relapsed/refractory cancer, with activity across multiple difficult-to-treat settings.
- Metastatic non-squamous non-small cell lung cancer
- Unresectable or metastatic hepatocellular carcinoma
- Advanced-stage relapsed/refractory solid tumors
- Colorectal cancer and mixed solid tumor cohorts
The sponsor’s oncology portfolio also includes patients with prior anti-PD-1/PD-L1 treatment exposure and limited remaining standard options.
Immuno-oncology and checkpoint-based combinations
Its trials examine the use of GDF-15-targeted therapy alongside established immune checkpoint inhibitors in several tumor types.
- Visugromab
- Nivolumab
- Anti-PD-1 checkpoint inhibition
- Combination immunotherapy
Research activity spans both treatment-experienced and treatment-naive cancer populations, with interest in enhancing anti-tumor responses through immunotherapy combinations.
Bladder cancer and perioperative treatment
The sponsor funds studies in muscle-invasive bladder cancer, including neoadjuvant settings for patients preparing for radical surgery and those unable to receive cisplatin-based chemotherapy.
- Muscle invasive bladder cancer
- Neoadjuvant immunotherapy
- Radical cystectomy
- Cisplatin-ineligible disease
These studies place emphasis on preoperative cancer control and immunotherapy-based approaches in urothelial malignancy.
Cancer-associated cachexia and metabolic complications
CatalYm GmbH also supports research in cancer-associated cachexia, addressing the systemic and nutritional burden that accompanies advanced malignancy.
- Cachexia
- Weight loss in cancer
- Metabolic wasting syndromes
This area reflects interest in the supportive care dimensions of oncology, particularly symptoms linked to disease progression and reduced functional status.
